Showing posts with label FDA. Show all posts
Showing posts with label FDA. Show all posts

Sunday, August 22, 2010

Moral of the story: A new 5 day emergency contraceptive drug is now on the market.  Previously the only option was a 2 day EC.

Source: AMA Morning Rounds 8/16/10


FDA approves new five-day emergency contraceptive.

NBC Nightly News (8/13, story 8, 0:15, Curry) reported, "Today, federal health officials approved a new type of morning after contraceptive that reduces the chance of pregnancy for five days. That's two days longer than the emergency contraception known as Plan B. The new pill is called Ella and it will be available by prescription only."
        The AP (8/14, Perrone) reported that the FDA on Friday approved a new type of morning-after contraceptive, Ella from HRA Pharma, a prescription-only birth control option that reduces the chance of pregnancy up to five days after sex. Ella "uses the hormone progesterone to delay ovulation, a key step in the fertilization process. Despite this, the drug has drawn criticism from anti-abortion groups who say it is closer to an abortion pill than an emergency contraception pill. Groups including the Family Research Council argue the drug is chemically similar to the abortion drug mifeprestone, which can be taken to end a pregnancy up to 50 days into the gestation period."
        The Los Angeles Times (8/14, Maugh II) "Booster Shots" blog said that the drug, "known generically as ulipristal acetate, is thought to inhibit or delay ovulation by interfering with the effects of the female hormone progesterone, which stimulates ovulation. ... Women with a known or suspected pregnancy or who are breastfeeding should not use the drug."
        The Washington Post (8/14, Stein) said that Ella "can cut the chances of becoming pregnant by about two-thirds for at least 120 hours after a contraceptive failure or unprotected sex, studies have shown." Supporters and opponents both said the FDA's decision "marked the clearest evidence of a shift in the influence of political ideology at the FDA. ... If the history of Plan B is any indication, Ella's approval is likely to mark the beginning of many years of political and regulatory battles over the drug."
        The New York Times (8/14, A1, Harris) reported on its front page that "some advocates said Friday that the agency's relatively rapid adoption of its scientists' advice meant that its traditional separation from political considerations had returned. 'It's really important the FDA made a decision that's based on the scientific evidence and not on the political controversy,' said Diana Zuckerman, president of the National Research Center for Women and Families. But Wendy Wright, president of Concerned Women for America, which opposes abortion, said that political considerations were still at work inside the agency."
        The Wall Street Journal (8/14, Mathews, Dooren) noted that the label says ulipristal likely works by inhibiting or delaying ovulation, but its efficacy also may be partly due to an effect of altering the lining of the uterus in a way that affects implantation.
        Bloomberg News (8/14, Waters, Peterson) noted, "Side effects among the 2,600 women who took part in studies included nausea, headache, abdominal pain and dizziness. Ella shouldn't be used when a woman is pregnant or suspects she may be, Watson said in the statement." In addition, "women who become pregnant or complain of lower abdominal pain after taking the drug should be examined for the possibility that an egg has become fertilized and lodged outside the uterus, the company said."MedPage Today (8/13, Gever) and WebMD (8/13, DeNoon) also covered the story.

Tuesday, August 3, 2010

Ketamine may be promising treatment for depression among patients with bipolar disorde

Moral of the story:  While it may sound scary, Ketamine has been used for a variety of purposes and may hold promise in an area still looking for a good drug.

Source: AMA Morning Rounds 8/3/2010


Ketamine may be promising treatment for depression among patients with bipolar disorder.

The Los Angeles Times (8/2, Roan) "Booster Shots" blog reported that the prescription medication ketamine [ketamine hydrochloride], which is "used as an anesthetic -- and used illegally as a party drug at raves -- may have a role in treating people with bipolar depression, according to astudy " published August 2 in the Archives of General Psychiatry. In a study of 18 patients, "researchers at the National Institute of Mental Health found that 71% of the bipolar patients who had not responded to other treatments, experienced significant improvement in depression symptoms after a single intravenous infusion of ketamine. Most of these patients responded within 40 minutes of receiving the drug," and the effects lasted for approximately three days.
        Time (8/3, Cloud) reports, "All patients were randomly and blindly given one 0.5 mg/kg dose of ketamine and one equal dose of placebo saline through an IV drip two weeks apart. Patients taking ketamine were significantly more likely than those on the placebo to show short-term improvement in their depression symptoms. This is crucial for bipolar patients who are in depressive crisis and at high risk of suicide: if you can give them something to block short-term suicidal impulses, you may be able to settle them -- and then treat them for long-term problems."
        "Ketamine acts on the brain's glutamatergic system, which plays a role in information processing and memory formation,"HealthDay (8/2, Preidt) reported. "Recent research suggests that dysfunction in this brain system may contribute to bipolar disorder, noted Dr. Nancy Diazgranados and colleagues at the US National Institute of Health." But, even though "ketamine has been used off-label as an experimental treatment for depression, it has not been approved by the US Food and Drug Administration for that use, according to the US National Institutes of Health." WebMD (8/2, Woznicki) also covered the study.

Monday, May 24, 2010

Pill for female sex drive

Moral of the story: a possibly unnecessary an dangerous drug that targets female arousal.

Source: AMA Morning Rounds 5/24/2010

FDA advisory committee to consider approving pill designed to boost women's sex lives.
The Washington Post (5/24, Stein) reports, "A panel of federal advisers will soon" consider "endorsing the first pill designed to do for women what Viagra [sildenafil] did for men: boost their sex lives." The drug known as "flibanserin," which was developed by Germany's Boehringer Ingelheim, may become "the first prescription medication to tap what some have estimated could be a $2 billion market in the United States alone." But, "even before the FDA's Reproductive Health Drugs Advisory Committee meets June 18 to consider the request, the prospect of the drug's approval has triggered debate over whether the medication, like others in the pipeline, represents a long-sought step toward equity for women's health or the latest example of the pharmaceutical industry fabricating a questionable disorder to sell unnecessary -- and potentially dangerous -- drugs."
The creator of a new documentary on "female sexuality" stumbled upon the issue while researching her film, Newsweek (5/23, Kantrowitz, Wingert) reported. Liz Canner "was bewildered by the purported disease" that some refer to as "female sexual dysfunction." Noting that Vivus executives told her that "43 percent of women had this disorder," Canner asked, "How could that be true if I had never heard of it before?" After "a cross-country quest that included visits with scientists, experts in erotica, and individual women," Canner "ultimately concluded that the catch-all female sexual dysfunction is essentially a phony disease made up by pharmaceutical companies."



- Posted using BlogPress from my iPhone

Sunday, March 21, 2010

Hearing aid with no externally visible components receives FDA approval.

Moral of the story: A hearing aid no one else can see.  cool. necessary?

Source: AMA Morning Rounds 3/18/2010


Hearing aid with no externally visible components receives FDA approval.


The Los Angeles Times (3/17, Healy) "Booster Shots" blog reported, "For several decades, people with hearing loss due to noise, viral infections or aging have had hearing aids to help maintain an aural tie to the world." Now, after a receiving approval from the FDA, "these patients will" have access to "a surgically implantable hearing system called Esteem." What's more, the "new device is considered to be the first hearing aid that has no externally visible components."

Sunday, November 29, 2009

Generic drug use can help save money

Moral of the story: Generics are low cost, and THE EXACT SAME THING as name brand pharmaceuticals. This is the obvious way to save, but there are also cheaper options within the same family of drug that work just as well, or as well as you may need. While physicians don't have all the answers, they do have access to extensive drug information they can use to help you save.

Source: AMA Morning Rounds 11/5/09

Asking physicians about generic drugs seen as key to cutting prescription costs.

The AP (11/5, Perrone) reports, "The senior advocacy group AARP reports that prices for the most popular drugs rose 8.7 percent on average last year, more than twice the rate of inflation." And "last year, pharmaceutical companies spent more than $4 billion urging patients like you to 'ask your doctor' about their drugs. But, if you want a prescription that won't empty your wallet, while still keeping you well, you might start asking your doctor about drugs you don't see on TV." For instance, "AstraZeneca's acid reflux drug Nexium [esomeprazole magnesium] -- the 'purple pill' -- was the second best-selling drug in the US last year, with a hefty price tag of about $215 per month. But, a drug from the same family, that works the same way, is available over-the-counter for about $20 a month as Prilosec [omeprazole]."

Friday, November 20, 2009

Spray-on anesthetic helps delay ejaculation.

Moral of the story: One of those awkward doorknob questions just got a better answer.

Source: AMA Morning Rounds 11/20/09

Bloomberg News (11/20, Matsuyama) reports, "A spray-on treatment for premature ejaculation may prolong sexual intercourse by as much as five times." In fact, the drug, known as PSD502, "delayed orgasm by an average of 108 seconds" after one month of treatment, according to a 256-patient trial conducted in Canada, Poland, and the US.

The work may benefit the estimated "one in three US men ages 18 to 59" who have dealt with the problem at one time or another, according to the Los Angeles Times (11/19, Maugh) "Booster Shots" blog. That's "about twice as many as those who suffer from erectile dysfunction." Indeed, "some antidepressant-like drugs, such as dapoxetine, have been approved in a few countries to treat the condition, but the Food and Drug Administration rejected it because of long-term side effects." And while "some physicians prescribe anesthetic creams like EMLA cream...off-label," they "require 45 minutes to work."

Now, researchers at the University of California-San Francisco may have stumbled upon a solution. According to WebMD (11/19, DeNoon), the spray "contains the anesthetics lidocaine and prilocaine," but it "doesn't deaden feeling, thanks to an ingredient in the spray that allows it to rapidly penetrate the skin." What's more, it "seems safe for men's female sex partners," as "only about 0.5% of female partners report decreased feeling in the vagina."

In light of those findings, HealthDay (11/19, Preidt) pointed out, "Sciele Pharma plans to seek US Food and Drug Administration approval of the spray." Reuters (11/20), the UK's Telegraph (11/19), and the UK's Press Association (11/19) also covered the story.

Friday, June 26, 2009

Tobacco, Public Health, and the FDA

Moral of the story: The FDA and local governments can now finally treat tobacco as the addictive substance that it is, protecting the health of Americans and decreasing costs ($96B).

Tobacco, Public Health, and the FDA
Gregory D. Curfman, M.D., Stephen Morrissey, Ph.D., and Jeffrey M. Drazen, M.D.
Published at www.nejm.org June 22, 2009 (10.1056/NEJMe0905622)

More than a decade ago, David Kessler, then Commissioner of the Food and Drug Administration (FDA), launched a bold initiative to regulate tobacco. He believed that since nicotine is an addictive substance, it fell under the statutory authority of the FDA to regulate it as a drug and cigarettes as the delivery vehicle.
His effort failed, however, when the U.S. Supreme Court decided in a 5-to-4 ruling (FDA v. Brown & Williamson Tobacco Corp.) that the Food, Drug, and Cosmetic Act of 1938, which defined the FDA's authority, did not grant the agency jurisdiction to regulate tobacco. Writing for the Court, Justice Sandra Day O'Connor concluded that "it is plain that Congress has not given the FDA the authority to regulate tobacco products."1 The Court's decision was based on its reading of the statutory language in the act, not on what was best for the health of the public.
Today, President Barack Obama changed all that. With the signing of the Family Smoking Prevention and Tobacco Control Act of 2009, which was passed by sizable majorities in both the House and the Senate (and which we endorsed), the FDA has been given broad authority to regulate tobacco products. We believe that this historic legislation can have an unparalleled positive impact on the health of the American public.
The act establishes the Center for Tobacco Products, a unit within the FDA that will be funded by user fees from tobacco manufacturers and importers — $235 million in fiscal year 2010, rising to $712 million over the next 10 years. The center is charged with regulating tobacco products for the explicit purpose of protecting the health of the public. The FDA will now have the authority to require that all ingredients, compounds, and additives in tobacco products be reported to the agency, and those found to have harmful health effects may be banned. Nicotine levels in cigarettes may be regulated, but neither nicotine nor cigarettes may be banned outright. In keeping with the act's focus on protecting those under 18 years of age, flavorings in cigarettes, which are meant to appeal to young smokers, are banned, with the exception of menthol, which could be banned later if found to be a health hazard. No new tobacco product can be marketed unless first approved by the FDA.
Importantly, the act will also allow regulation of so-called modified risk tobacco products, which are typically identified by terms on the package such as "light," "low," or "mild." The use of such terms will no longer be permitted unless the product has been shown to significantly reduce harm. Warning labels on cigarette packages will be made more graphic and will require the use of color. Tobacco companies may no longer sponsor sporting events.
For the first time in almost 40 years, state and local governments will be allowed to regulate the marketing of tobacco, establishing restrictions that may be more rigorous than those of the FDA. In addition, the act requires that the 1996 Tobacco Rule, which was put in place by Commissioner Kessler and deemed unconstitutional by the Supreme Court, must be reinstated. This rule places restrictions on tobacco advertising, including a ban on outdoor advertising within 1000 ft of a school. It is anticipated that this regulation may be the focus of a constitutional challenge on the basis that such advertising represents commercial speech subject to First Amendment protection. Still, there is good reason to believe that this carefully crafted provision, which is narrowly tailored to focus on smoking prevention in the nation's young, will survive any such legal challenge.
The long-term impact of the Family Smoking Prevention and Tobacco Control Act on the health of the public will depend critically on its implementation through strict regulations, rigorously enforced. FDA Commissioner Margaret Hamburg and Principal Deputy Commissioner Joshua Sharfstein promise to be strong advocates for rigorous enforcement.
In a recent article in the Journal, Hamburg and Sharfstein laid out their new mission.2 They regard the FDA as a public health agency whose purpose is not just to regulate the nation's food and drug supplies, but to protect the health of American citizens. Hamburg has also indicated that she is eager to undertake the regulation of tobacco and said in an interview, "We now have an opportunity to really make a difference with what is probably the No. 1 public health concern in the nation and the world."3
Few threats to the health of the public are as onerous as tobacco. Each year more than 435,000 Americans die of tobacco-related illnesses, principally heart, vascular, and lung diseases. Tobacco use is also associated with substantial morbidity and diminished quality of life. More than one in five Americans still smoke, an astonishing figure given the overwhelming evidence of harm. In addition to excess morbidity and mortality, tobacco adds considerably to health care costs at a time when reducing costs is a national priority. The total annual health care expenditures caused by smoking run to $96 billion.4 Along with other critical prevention goals, such as controlling obesity and increasing levels of physical activity, the elimination of cigarette smoking is central to improving the health of our citizens and mitigating the growth of health care costs.
The Family Smoking Prevention and Tobacco Control Act of 2009 comes at a propitious moment in U.S. history. We strongly support the FDA's new leaders and urge them to implement the act aggressively. As a medical journal, we are committed to eliminating the public health threat tobacco represents to American society and the world.
Source Information
This article (10.1056/NEJMe0905622) was published on June 22, 2009, at NEJM.org.
References

FDA v. Brown & Williamson Tobacco Corp. 529 U.S. 120 (2000).
Hamburg MA, Sharfstein JM. The FDA as a public health agency. N Engl J Med 2009;360:2493-2495. [Free Full Text]
Harris G. New F.D.A. chief says she'll toughen enforcement efforts. New York Times. June 17, 2009:A19.
Campaign for Tobacco-free Kids. Toll of tobacco in the United States of America. April 2009. (Accessed June 22, 2009, at http://www.tobaccofreekids.org/research/factsheets/pdf/0072.pdf.)

Friday, January 23, 2009

F.D.A. Approves a Stem Cell Trial - And It Is Probably Not A Good Thing

Moral of the story: Playing with fire. This is not the trial that should be done first for embryonic stem cells. The backlash to poor results, which are likely given the data thus far, could be absolutely tremendous. This is yet another example of the FDA doing a shitty job at regulating pharma. Shame on Gera and shame on the FDA and shame on former President Bush.

F.D.A. Approves a Stem Cell Trial
http://www.nytimes.com/2009/01/23/business/23stem.html?ref=health

By ANDREW POLLACK
Published: January 23, 2009
In a research milestone, the federal government will allow the world’s first test in people of a therapy derived from human embryonic stem cells.

Federal drug regulators said that political considerations had no role in the decision. Nevertheless, the move coincided with the inauguration of President Obama, who has pledged to remove some of the financing restrictions placed on the field by President George W. Bush.
The clearance of the clinical trial — of a treatment for spinal cord injury — is to be announced Friday by Geron, the biotechnology company that first applied to the Food and Drug Administration to conduct the trial last March. The F.D.A. had first said no, asking for more data.
Thomas B. Okarma, Geron’s chief executive, said Thursday that he did not think that the Bush administration’s objections to embryonic stem cell research played a role in the F.D.A.’s delaying approval.
“We really have no evidence,” Dr. Okarma said, “that there was any political overhang.”
But others said they suspected it was more than a coincidence that approval was granted right after the new administration took office.
“I think this approval is directly tied to the change in administration,” said Robert N. Klein, the chairman of California’s $3 billion stem cell research program. He said he thought the Bush administration had pressured the F.D.A. to delay the trial.
Mr. Klein called the approval of the first human trial of this sort “an extraordinary benchmark.”
Stem cells derived from adults and fetuses are already being used in some clinical trials, but they generally have less versatility than embryonic stem cells in terms of what tissue types they can form.
The F.D.A. approval comes a little more than 10 years after the first human embryonic stem cells were isolated at the University of Wisconsin, in work financed by Geron.
Because the cells can turn into any type of cell in the body, the theory is they may one day be able to provide tissues to replace worn-out organs or nonfunctioning cells to treat diabetes, heart attacks and other diseases. The field is known as regenerative medicine.
The Bush administration restricted federal financing for research on embryonic stem cells because creation of the cells entails the destruction of human embryos.
Geron’s trial will involve 8 to 10 people with severe spinal cord injuries. The cells will be injected into the spinal cord at the injury site 7 to 14 days after the injury occurs, because there is evidence the therapy will not work for much older injuries.
The study is a so-called Phase I trial, aimed mainly at testing the safety of the therapy. There would still be years of testing and many hurdles to overcome before the treatment would become routinely available to patients.
Geron, which is based in Menlo Park, Calif., said that it had identified up to seven medical centers for the trial but that those sites must first get permission from their own internal review boards to participate.
Even as some researchers hailed the onset of clinical trials, others expressed trepidation that if the therapy proves unsafe — or even if it is safe but does not work — it could cause a backlash that would set the field back for years.
“It would be a disaster, a nightmare, if we ran into these kinds of problems in this very first trial,” said Dr. John A. Kessler, the chairman of neurology and director of the stem cell institute at Northwestern University.
Dr. Kessler, whose own daughter was paralyzed from the waist down in a skiing accident, said he thought Geron’s therapy was not the ideal candidate for the first trial. He said results showing the therapy worked in moderately injured animals might not apply to more seriously injured people.
“We really want the best trial to be done for this first trial, and this might not be it,” he said.
Dr. Okarma of Geron emphasized that the purpose of the first trial was safety, so that lack of efficacy should not be a problem. While researchers will also look for signs the treatment works, he said, the best that could be hoped for would be some slight restoration of function that could then be enhanced through physical therapy.
“We don’t expect to take someone who is completely paralyzed from the waist down and have them dance six months later,” he said. If the first trial shows safety, the company would then hope to test higher doses of cells and treat patients with less severe injuries, he said.
Geron’s therapy involves using various growth factors to turn embryonic stem cells into precursors of neural support cells called oligodendrocytes, which are then injected into the spinal cord at the site of the injury.
The hope is that the injected cells will help repair the insulation, known as myelin, around nerve cells, restoring the ability of some nerve cells to carry signals. There is also some hope that growth factors produced by the injected cells will spur damaged nerve cells to regenerate.
The therapy was developed in collaboration with Hans Keirstead of the University of California, Irvine. He has shown videos of paralyzed rats that were able to walk again, albeit imperfectly, after receiving the therapy. Those videos helped persuade California voters to approve the $3 billion stem cell research program in 2004.
The main safety concern is that if raw embryonic cells are put into the body, they can form tumors. Even though most such tumors do not spread like other cancers, any unwanted growth in the spinal cord can further damage nerves.
“It’s not ready for prime time, at least not in my mind, until we can be assured that the transplanted stem cells have completely lost the capacity for tumorogenicity,” said Dr. Steven Goldman, chairman of neurology at the University of Rochester. He was a member a committee convened by the F.D.A. last April to examine the safety aspects of trials using therapies from embryonic stem cells.
Dr. Okarma said Geron had done numerous studies showing that its cells did not contain residual embryonic cells and did not form tumors in animals even after a year. It submitted 22,000 pages of data to the F.D.A., perhaps the largest application ever for permission to begin a clinical trial.
The embryonic stem cell line used by Geron is one of the oldest ones and was therefore eligible for federal financing under the Bush administration’s policy, Dr. Okarma said.
Nevertheless, Geron paid for its own work, spending $45 million to prepare its F.D.A. application.
Geron, which was formed in 1990 as an antiaging company, is still in the development stage and is not yet profitable, having lost about $500 million since its inception. Besides working on stem cells, it is testing drugs for cancer that influence telomeres, the caps on the ends of chromosomes that help control the aging of cells. Geron’s market value is about $400 million.
While the Bush administration’s policy did not impede the company’s application at the F.D.A., Dr. Okarma said, it did slow progress for the field in general by making it hard for academics to do research.
“It is the private sector that has kept the technology alive so that it can see the light of day in a clinical trial,” he said.
Mr. Klein of the California stem cell program said he thought the next trial might be of a treatment for macular degeneration, an eye disease, that is being developed in Britain.
In the last couple of years, some attention has turned away from embryonic stem cells to a newer technique that allows a patient’s own skin cells to be turned into a cell resembling such embryonic cells.
That might do away with the need for embryos. And the resulting tissue made from those cells would match the patient, doing away with the need for immune suppression to prevent rejection of the transplant. Geron said its trial would require only temporary use of low doses of immune-suppressing drugs.
But the newer technique involves putting genes into the skin cells using viruses, which also raises a risk of cancer.